Dual anti-platelet therapy in secondary stroke prevention

Auteur(s): Springer Healthcare IME
Écouter gratuitement

  • Résumé

  • Professor Marc Fisher and Springer Healthcare IME invite you to listen to these three podcast discussions with experts in this therapy area. The podcasts focus on the clinical implications of recently published results from clinical trials involving the use of dual-anti-platelet therapy for secondary stroke prevention.
    Springer Healthcare. Part of the Springer Nature Group.
    Voir plus Voir moins
Hygiene & Healthy Living Science Sciences biologiques Troubles et maladies
Voir plus Voir moins
Épisodes
  • Discussion of the CHANCE and PRINCE clinical trials (with Marc Fisher and Liping Liu)

    Discussion of the CHANCE and PRINCE clinical trials (with Marc Fisher and Liping Liu)
    Mar 2 2021

    Professors Marc Fisher and Liping Liu discuss the CHANCE and PRINCE clinical trials focusing on their backgrounds and key results, and commenting on their clinical implications.

    This programme is made possible thanks to an independent educational grant from AstraZeneca.

    Find more information at https://ime.springerhealthcare.com/programs/emerging-dual-anti-platelet-therapy-strategies-for-neurologists-in-secondary-stroke-prevention/
    Voir plus Voir moins
    18 min
  • Discussion on the POINT trial (with Marc Fisher and Greg Albers)

    Discussion on the POINT trial (with Marc Fisher and Greg Albers)
    Mar 2 2021

    Professor Marc Fisher and Dr Greg Albers discuss the POINT trial, also commenting on when to consider ticagrelor versus clopidogrel.

    This programme is made possible thanks to an independent educational grant from AstraZeneca.

    Find more information at https://ime.springerhealthcare.com/programs/emerging-dual-anti-platelet-therapy-strategies-for-neurologists-in-secondary-stroke-prevention/
    Voir plus Voir moins
    18 min
  • Discussion on the THALES trial and the clinical implications of the CHANCE 2 trial (with Marc Fisher and Clay Johnston)

    Discussion on the THALES trial and the clinical implications of the CHANCE 2 trial (with Marc Fisher and Clay Johnston)
    Mar 2 2021

    Professor Marc Fisher and Dr Clay Johnston discuss the THALES trial, explaining its rationale, key results and subgroup analyses, and also comment on the potential clinical implications of CHANCE 2.

    This programme is made possible thanks to an independent educational grant from AstraZeneca.

    Find more information at https://ime.springerhealthcare.com/programs/emerging-dual-anti-platelet-therapy-strategies-for-neurologists-in-secondary-stroke-prevention/
    Voir plus Voir moins
    22 min

Ce que les auditeurs disent de Dual anti-platelet therapy in secondary stroke prevention

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Évaluations sur Audible.ca

Évaluations sur Amazon.ca
Il n'y a pas encore de critiques pour ce titre.